Melissa L. Boby,Daren Fearon,Matteo Ferla,Mihajlo Filep,Lizbé Koekemoer,Matthew C. Robinson,The COVID Moonshot Consortium‡,John D. Chodera,Alpha A. Lee,Nir London,Annette von Delft,Frank von Delft,Hagit Achdout,Anthony Aimon,Dominic S. Alonzi,Robert Arbon,Jasmin C. Aschenbrenner,Blake H. Balcomb,Elad Bar-David,Haim Barr,Amir Ben-Shmuel,James Bennett,Vitaliy A. Bilenko,Bruce Borden,Pascale Boulet,Gregory R. Bowman,Lennart Brewitz,Juliane Brun,BVN Sarma,Mark Calmiano,Anna Carbery,Daniel W. Carney,Emma Cattermole,Edcon Chang,Eugene Chernyshenko,Austin Clyde,Joseph E. Coffland,Galit Cohen,Jason C. Cole,Alessandro Contini,Lisa Cox,Tristan Ian Croll,Milan Cvitkovic,Steven De Jonghe,Alex Dias,Kim Donckers,David L. Dotson,Alice Douangamath,Shirly Duberstein,Tim Dudgeon,Louise E. Dunnett,Peter Eastman,Noam Erez,Charles J. Eyermann,Michael Fairhead,Gwen Fate,Oleg Fedorov,Rafaela S. Fernandes,Lori Ferrins,Richard Foster,Holly Foster,Laurent Fraisse,Ronen Gabizon,Adolfo García-Sastre,Victor O. Gawriljuk,Paul Gehrtz,Carina Gileadi,Charline Giroud,William G. Glass,Robert C. Glen,Itai Glinert,Andre S. Godoy,Marian Gorichko,Tyler Gorrie-Stone,Ed J. Griffen,Amna Haneef,Storm Hassell Hart,Jag Heer,Michael Henry,Michelle Hill,Sam Horrell,Qiu Yu Judy Huang,Victor D. Huliak,Matthew F. D. Hurley,Tomer Israely,Andrew Jajack,Jitske Jansen,Eric Jnoff,Dirk Jochmans,Tobias John,Benjamin Kaminow,Lulu Kang,Anastassia L. Kantsadi,Peter W. Kenny,J. L. Kiappes,Serhii O. Kinakh,Boris Kovar,Tobias Krojer,Van Ngoc Thuy La,Sophie Laghnimi-Hahn,Bruce A. Lefker,Haim Levy,Ryan M. Lithgo,Ivan G. Logvinenko,Petra Lukacik,Hannah Bruce Macdonald,Elizabeth M. MacLean,Laetitia L. Makower,Tika R. Malla,Peter G. Marples,Tatiana Matviiuk,Willam McCorkindale,Briana L. McGovern,Sharon Melamed,Kostiantyn P. Melnykov,Oleg Michurin,Pascal Miesen,Halina Mikolajek,Bruce F. Milne,David Minh,Aaron Morris,Garrett M. Morris,Melody Jane Morwitzer,Demetri Moustakas,Charles E. Mowbray,Aline M. Nakamura,Jose Brandao Neto,Johan Neyts,Luong Nguyen,Gabriela D. Noske,Vladas Oleinikovas,Glaucius Oliva,Gijs J. Overheul,C. David Owen,Ruby Pai,Jin Pan,Nir Paran,Alexander Matthew Payne,Benjamin Perry,Maneesh Pingle,Jakir Pinjari,Boaz Politi,Ailsa Powell,Vladimír Pšenák,Iván Pulido,Reut Puni,Victor L. Rangel,Rambabu N. Reddi,Paul Rees,St Patrick Reid,Lauren Reid,Efrat Resnick,Emily Grace Ripka,Ralph P. Robinson,Jaime Rodriguez-Guerra,Romel Rosales,Dominic A. Rufa,Kadi Saar,Kumar Singh Saikatendu,Eidarus Salah,David Schaller,Jenke Scheen,Celia A. Schiffer,Christopher J. Schofield,Mikhail Shafeev,Aarif Shaikh,Ala M. Shaqra,Jiye Shi,Khriesto Shurrush,Sukrit Singh,Assa Sittner,Peter Sjö,Rachael Skyner,Adam Smalley,Bart Smeets,Mihaela D. Smilova,Leonardo J. Solmesky,John Spencer,Claire Strain-Damerell,Vishwanath Swamy,Hadas Tamir,Jenny C. Taylor,Rachael E. Tennant,Warren Thompson,Andrew Thompson,Susana Tomásio,Charles W. E. Tomlinson,Igor S. Tsurupa,Anthony Tumber,Ioannis Vakonakis,Ronald P. van Rij,Laura Vangeel,Finny S. Varghese,Mariana Vaschetto,Einat B. Vitner,Vincent Voelz,Andrea Volkamer,Martin A. Walsh,Walter Ward,Charlie Weatherall,Shay Weiss,Kris M. White,Conor Francis Wild,Karolina D. Witt,Matthew Wittmann,Nathan Wright,Yfat Yahalom-Ronen,Nese Kurt Yilmaz,Daniel Zaidmann,Ivy Zhang,Hadeer Zidane,Nicole Zitzmann,Sarah N. Zvornicanin,Sarma BVNBS,

Abstract:We report the results of the COVID Moonshot, a fully open-science, crowdsourced, and structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease. We discovered a noncovalent, nonpeptidic inhibitor scaffold with lead-like properties that is differentiated from current main protease inhibitors. Our approach leveraged crowdsourcing, machine learning, exascale molecular simulations, and high-throughput structural biology and chemistry. We generated a detailed map of the structural plasticity of the SARS-CoV-2 main protease, extensive structure-activity relationships for multiple chemotypes, and a wealth of biochemical activity data. All compound designs (>18,000 designs), crystallographic data (>490 ligand-bound x-ray structures), assay data (>10,000 measurements), and synthesized molecules (>2400 compounds) for this campaign were shared rapidly and openly, creating a rich, open, and intellectual property–free knowledge base for future anticoronavirus drug discovery.

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structure-based Virtual Screening, in Silico Docking, ADME Properties Prediction and Molecular Dynamics Studies for the Identification of Potential Inhibitors Against SARS-CoV-2 Mpro.

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Drug Discovery in Low Data Regimes: Leveraging a Computational Pipeline for the Discovery of Novel SARS-CoV-2 Nsp14-MTase Inhibitors

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

Computationally driven discovery of SARS-CoV-2 Mpro inhibitors: from design to experimental validation

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses

A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**

Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease

Targeting the Main Protease (M pro , nsp5) by Growth of Fragment Scaffolds Exploiting Structure-Based Methodologies

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Large library docking for novel SARS‐CoV‐2 main protease non‐covalent and covalent inhibitors

Large-Scale Recombinant Production of the SARS-CoV-2 Proteome for High-Throughput and Structural Biology Applications

Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity

De Novo Design and Bioactivity Prediction of SARS-CoV-2 Main Protease Inhibitors Using ULMFit

Extensive exploration of structure activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment merging and active learning

Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease